Olaparib (AZD2281, Ku-0059436)

目录号:S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂,IC50为5 nM/1 nM,其对PARP1/2的作用比对Tankyrase-1效果高300倍。

规格 价格 库存 购买数量  
RMB 745.41 现货
RMB 571.54 现货
RMB 1219.52 现货
RMB 3019.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献92篇:

客户使用该产品的18个实验数据:

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂,IC50为5 nM/1 nM,其对PARP1/2的作用比对Tankyrase-1效果高300倍。
特性 Olaparib是第一批PARP抑制剂之一。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
体外研究

Olaparib是PARP抑制剂,也作用于BRCA1或BRCA2突变。Olaparib对端锚(聚合)酶-1作用效果不大,IC50值大于。Olaparib浓度为30-100 nM作用于SW620细胞,使PARP-1失活。与BRCA1和BRCA2充足细胞系(Hs578T,MDA-MB-231,T47D)相比,BRCA1缺陷细胞系(MDA-MB-463和HCC1937)对Olaparib过分敏感[1] Olaparib抑制PARP,阻断碱基切除修复,导致KB2P细胞对Olaparib强烈敏感。结果导致在DNA复制时由单链断裂转变为双链断裂,由此激活BRCA2依赖的重组途径。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NXn2eHRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvS[4k1KGR? MoC1TWM2OD13LkewOUAh|ryPIB?= MmjyNVg2PTl4MUO=
KP6.3 M3yyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjpOEBl M4PHc2lEPTB;MUCuOFI5KM7:TTC= NFXHPG4yQDV3OU[xNy=>
KP7.7 NEHHPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO0JIQ> MoTITWM2OD13NzDuUUA> M3\EOFE5PTV7NkGz
KB2P3.4 M1nITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftOEBl NWjiW4o5UUN3ME2xNlQhVSB? MkPRNVg2PTl4MUO=
KB2P1.21 NULRO405T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG0JIQ> MVzJR|UxRTh7MEegcm0h NGT4TlMyQDV3OU[xNy=>
U373-MG MVrDfZRwfG:6aXOgRZN{[Xl? MXKxJO69VSB? M4\mVVI1KGh? M3O3W2lv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? M4rq[VE5QTV2N{Gy
T98G NXXFU45iS3m2b4TvfIlkKEG|c3H5 NVe2Xm9LOSEQvF2g NULFRWM3OjRiaB?= MWHJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 NH;OUpEyQDl3NEexNi=>
U87-MG MlLUR5l1d3SxeHnjJGF{e2G7 Mn3ONUDPxE1i Ml3CNlQhcA>? NWfTS3J1UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= MV6xPFk2PDdzMh?=
UVW MULDfZRwfG:6aXOgRZN{[Xl? MnfKOVAxKG6P Mn3ZNlQhcA>? NY\oUJE2UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= Mnq2NVg6PTR5MUK=
HeLa NEHrbnRHfW6ldHnvckBCe3OjeR?= M2n6UVUxOCCwTR?= M4XaRVQhcA>? M37sVWNifXOnczDhJI1w\GW|dDDk[YxigSCrbjDy[YpwcW6rbnegc4YhemGmaXH0bY9vNWmwZIXj[YQhTE6DIHLy[YFsew>? NHTn[ZUyQDl3NEexNi=>
HeLa MlL0SpVv[3Srb36gRZN{[Xl? NES3OIsyKM7:TTC= MWOyOEBp M1Lsd2VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 M{PJRVE5QTV2N{Gy
T98G MmrOSpVv[3Srb36gRZN{[Xl? M3S4UVEh|ryPIB?= MlrJNlQhcA>? MlL2SY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? NYS2TIp5OTh7NUS3NVI>
L3 NGW0d41EgXSxdH;4bYMhSXO|YYm= MXK1JO69VSB? NEPCSFg6PiCq MkHJSG1UVw>? NILXd21UcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> NIn2VHgzODF{NES1PS=>
Granta-519 M2LV[GN6fG:2b4jpZ{BCe3OjeR?= Ml\EOUDPxE1i MkLNPVYhcA>? M{flXGROW09? MkGzV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NE\FTHIzODF{NES1PS=>
BT NES4TmtEgXSxdH;4bYMhSXO|YYm= NIe4NZM2KM7:TTC= NEezeJI6PiCq NIm5[5RFVVOR MWfTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt Mmq5NlAyOjR2NUm=
UPN2 NWPjOmExS3m2b4TvfIlkKEG|c3H5 Mlz6OUDPxE1i MknEPVYhcA>? M3X1NGROW09? NYnsPWdsW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NUL4[GkyOjBzMkS0OVk>
HBL-2 MWjDfZRwfG:6aXOgRZN{[Xl? MXu1JO69VSB? NGXmZ3M6PiCq M{PaUmROW09? NVjTTml2W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MW[yNFEzPDR3OR?=
JVM-2 M{jzW2N6fG:2b4jpZ{BCe3OjeR?= MoD6OUDPxE1i NVS4O5dtQTZiaB?= MWfEUXNQ MoLYV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? MojGNlAyOjR2NUm=
Z138 NF3I[I5EgXSxdH;4bYMhSXO|YYm= NVvnfVBxPSEQvF2g MXi5OkBp MmrwSG1UVw>? MUjTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MXGyNFEzPDR3OR?=
RWPE MXzJcpZie2m4ZTDBd5NigQ>? MWqyOUDPxE1? MYe0PEBp MXjEUXNQ M4HNOHNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> NEL3UnozOTV5NUi2OS=>
VCaP M1ezcWlvfmG|aY\lJGF{e2G7 M{fBU|I2KM7:TR?= MUG0PEBp MnLLSG1UVw>? M2jjOnNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> MmTPNlE2PzV6NkW=
Mouse H2AX−/− ES Cells NF3HbZNEgXSxdH;4bYMhSXO|YYm= M1jVdVIvPSEQvF2= NEDmOm0zOCCq NY\YPIFbW2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NGHUdVAzOzN3NUS4PS=>
Mouse ATM−/− ES Cells NGT6eGVEgXSxdH;4bYMhSXO|YYm= MYSyMlUh|ryP NVLwOoo6OjBiaB?= M1\sN3Nq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> M{fnWVI{OzV3NEi5
H1650 NYPHdJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiyNEDPxE1? M3mwelE1PCCq NHzUXmRKSzVyPUG1MlQ4KM7:TR?= NXe4RZVGOjN{M{m4NFk>
H1650PTEN+ MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWyNEDPxE1? NEDHNHEyPDRiaB?= MkL1TWM2OD13MD64N{DPxE1? NH6xNXozOzJ|OUiwPS=>
PC-9 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2yNEDPxE1? MXKxOFQhcA>? NWnYXY86UUN3ME21Mlg5KM7:TR?= MWSyN|I{QThyOR?=
PC-9PTEN− NVz3NVRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInW[nIzOCEQvF2= NVXGT5l4OTR2IHi= MVPJR|UxRTZwNUKg{txO MkHMNlMzOzl6MEm=
MDA-MB-231 M1LYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe3N5FLPSCmYYm= MWHJR|UxRTZwOTFOwG0> M3fJPFI{PzZyNEm2
MDA-MB-468 M1zSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:4UVJSPSCmYYm= NYG0NVJjUUN3ME21MlAh|ryP MVqyN|c3ODR7Nh?=
BT20 M2nETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe1JIRigQ>? MWPJR|UxRTdwNzFOwG0> MVKyN|c3ODR7Nh?=
HCC1143 M{\2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG1JIRigQ>? MXXJR|UxRTFzLkGg{txO M2H4OVI{PzZyNEm2
HCC1937 NUm5fYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3aXlZtPSCmYYm= MorPTWM2OD1zMj62JO69VQ>? NH7pbJYzOzd4MES5Oi=>
Hs578t NIrYRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTyOGM3PSCmYYm= NHWzSY1KSzVyPUWuOkDPxE1? NW\Rd4lKOjN5NkC0PVY>
Hs578t(si) Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO1JIRigQ>? Mn;hTWM2OD15LkWg{txO MV2yN|c3ODR7Nh?=
BT474 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjJT242KGSjeR?= NF3ZXYRKSzVyPUG5Mlgh|ryP M37XPVI{PzZyNEm2
JIMT1 NV:3[3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL5O4M2KGSjeR?= M17PS2lEPTB;Nz63JO69VQ>? M3XDOlI{PzZyNEm2
SKBR3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\vOlUh\GG7 NWTVdppSUUN3ME2xNU4yKM7:TR?= M4DnRVI{PzZyNEm2
SUM159 MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC1JIRigQ>? NEe0e4NKSzVyPUSuNkDPxE1? M1\JV|I{PzZyNEm2
CAMA1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHwbXd2PSCmYYm= MW\JR|UxRTF3Lkig{txO NGP5ZZMzOzd4MES5Oi=>
MCF7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTsZpp2PSCmYYm= NVHmdnBSUUN3ME21Mlgh|ryP M4P0U|I{PzZyNEm2
T47D MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX61JIRigQ>? NX;JSoprUUN3ME25MlYh|ryP NXW3Wph2OjN5NkC0PVY>
HCT116 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjTRYNrOTByIN88US=> MnztOFghcA>? M3\UU2ROW09? M1njWmlEPTB;Mj61JO69VSB? NULlUYtMOjR3N{e5OFE>
SW1116 M3K2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:wOFMyODBizszN NXy2dnVmPDhiaB?= M1XaUGROW09? NHHScoJKSzVyPUGwNEDPxE1? MW[yOFU4Pzl2MR?=
HT29 NYrMd|FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETFRWQyODBizszN M4fVUVQ5KGh? NFjTS5BFVVOR NVH5Z2g4UUN3ME2xOE44KM7:TR?= NV7KeGMxOjR3N{e5OFE>
LoVo NInDUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\O[G1UOTByIN88US=> M{HERlQ5KGh? NF\zTphFVVOR MU\JR|UxRTF|LkSg{txO MnzwNlQ2Pzd7NEG=
HCT-15 M4nsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzqWnUyODBizszN MW[0PEBp NVTtWopbTE2VTx?= MWnJR|UxRTFyIN88US=> NFKwb5YzPDV5N{m0NS=>
SW48 NIGzZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[1bWg5OTByIN88US=> MXi0PEBp M4[zfWROW09? MlO3TWM2OD17LkWg{txO M3WydlI1PTd5OUSx
C-1 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D1SlExOCEQvF2= NG\NXpM1QCCq MYrEUXNQ MYfJR|UxRTdwNjFOwG0> M4XCSFI1PTd5OUSx
RKO MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljUNVAxKM7:TR?= NF;xU2s1QCCq NIDIeY5FVVOR NXPXSWRWUUN3ME21Mlkh|ryP NY\YOlVJOjR3N{e5OFE>
HCT116 M4myc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPoZ5llOTByIN88US=> MkLJOFghcA>? MXnEUXNQ NWHWc2hoWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MXGyOFU4Pzl2MR?=
SW1116 MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxNFAh|ryP MofROFghcA>? NH71RXJFVVOR M1\SSnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? M1\vRVI1PTd5OUSx
HT29 NXzTOFdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNFAh|ryP Mk[xOFghcA>? MmLRSG1UVw>? NVvpd5M1WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NWjWdY93OjR3N{e5OFE>
LoVo M4DJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPkXlkyODBizszN NYTFUm9MPDhiaB?= MmrNSG1UVw>? MWXQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh NEK5SFIzPDV5N{m0NS=>
SW48 NI[2b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrwNVAxKM7:TR?= M13nTlQ5KGh? M3\HU2ROW09? NEfpO2ZRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NFnmbJAzPDV5N{m0NS=>
C-1 NWnMVJdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWxNFAh|ryP M3\HXlQ5KGh? NEftc5VFVVOR M{HYbnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MoSyNlQ2Pzd7NEG=
RKO NEXFepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNFAh|ryP M4[0VFQ5KGh? M2rZVmROW09? MYnQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh M3Xlc|I1PTd5OUSx
HCT116 MWnGeY5kfGmxbjDBd5NigQ>? MmjXNVAhdk1? MorZNVIhcA>? MXvEUXNQ NYW2N|k1UW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 NYKzeIUyOjR3N{e5OFE>
HT29 MnzESpVv[3Srb36gRZN{[Xl? MX:xNEBvVQ>? MXmxNkBp NX\MSnNITE2VTx?= MkXxTY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 NITTXFAzPDV5N{m0NS=>
TE-6 MVvGeY5kfGmxbjDBd5NigQ>? NIPaZpQ2KM7:TTC= M1fxXFEzKGh? NHriXohFVVOR Mmr2TY5lfWOnczDHNk9OKGG{cnXzeC=> MlW5NlQzOTlzNkS=
TE-6 NWLEUIJXTnWwY4Tpc44hSXO|YYm= MUG1JO69VSB? MUKyOEBp MWLEUXNQ M{DNe2lv[3KnYYPld{BqdiCmb4XicIUhe3S{YX7kJIJz\WGtczCoSHNDeyl? NH;oOHozPDJzOUG2OC=>
Hep3B MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq0NEDPxE1i MmrIO|IhcA>? MYDEUXNQ MmjWV5lv\XKpaYP0bYNidGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJJdqfGhiRFjNSXE> NGPvXpozPTB5Mke1Ni=>
Huh7 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC0NEDPxE1i NFzQeHI4OiCq NUDUSmJoTE2VTx?= MYjTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=> M37YbVI2ODd{N{Wy
Hep3B MULGeY5kfGmxbjDBd5NigQ>? M1S1bVQxKM7:TTC= NWS1bZR1OjRiaB?= MnzMSG1UVw>? M2j0RWlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= NIG3bHozPTB5Mke1Ni=>
Huh7 NInVdpVHfW6ldHnvckBCe3OjeR?= M2nkWFQxKM7:TTC= MnjUNlQhcA>? M4\Rd2ROW09? MWrJcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? M4jvPVI2ODd{N{Wy
Hep3B MYrGeY5kfGmxbjDBd5NigQ>? NIP1bG41OCEQvF2g NGWzfm4zPCCq MUnEUXNQ NXjp[ZBLUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR NGntWYIzPTB5Mke1Ni=>
Huh7 NIPVXIZHfW6ldHnvckBCe3OjeR?= NX\CZ3p6PDBizszNJC=> NYCySlBZOjRiaB?= MYjEUXNQ NFzKUIhKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= M1XGblI2ODd{N{Wy
SGC-7901 NInzfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[0N|DDqM7:TR?= MYW0PEBp MUHEUXNQ NXTXW29XSmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp Mm\zNlU4PjdyN{[=
COLO-800 NVv4V4JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL2dIFKSzVyPUCuOFQyPjRizszN M1rSV3NCVkeHUh?=
EoL-1- NXXSbVFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnLRWVOUUN3ME2wMlU3PDR4IN88US=> MXPTRW5ITVJ?
NCI-H209 M2Hze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fEZmlEPTB;MD65NVU2PiEQvF2= MlruV2FPT0WU
ES1 NWTXR3pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMUG0NFgh|ryP NHfBT5lUSU6JRWK=
NKM-1 NE\QNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\3N5VKSzVyPUGuNlU{PDdizszN MWjTRW5ITVJ?
NTERA-S-cl-D1 NGjTUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwM{OzOFEh|ryP MmXSV2FPT0WU
MHH-ES-1 NIjaUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjRTJdzUUN3ME2xMlYzODZ5IN88US=> M13JPXNCVkeHUh?=
ES8 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHlWllKSzVyPUGuO|I1OTRizszN NWixbo5xW0GQR1XS
NCI-H720 M{Xadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj6bWZKSzVyPUKuNlA3QTlizszN MX7TRW5ITVJ?
EW-3 M3ztVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\hU|JKSzVyPUKuNlc2OzRizszN M2HDVXNCVkeHUh?=
D-566MG NEPWS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL5[GpGUUN3ME2yMlQ1PTZ6IN88US=> NIfPS4hUSU6JRWK=
697 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjaeFdIUUN3ME2yMlg1OTd|IN88US=> MXnTRW5ITVJ?
ES5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHJTWM2OD1{Lki4NVg6KM7:TR?= MX;TRW5ITVJ?
COLO-684 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNwNUG2PVYh|ryP NF;PZWVUSU6JRWK=
ML-2 NVvHUVRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDkdHlKSzVyPUOuOlAxPThizszN M{X4fHNCVkeHUh?=
MC-IXC NW\EVFVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGyT5RqUUN3ME2zMlY{Ozl|IN88US=> NELtfYpUSU6JRWK=
DB M4LiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILZe|dKSzVyPUOuOlU1PDhizszN NH22eItUSU6JRWK=
HCC2218 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G1NmlEPTB;Mz63N|ExOyEQvF2= Mk\vV2FPT0WU
NCI-H510A NETvO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNwOEK3NlQh|ryP NX\1bpQ{W0GQR1XS
NCI-H526 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvJTWM2OD1|Lki2PVU5KM7:TR?= MX3TRW5ITVJ?
MV-4-11 M2S4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7NPHdKSzVyPUSuNVM{OzRizszN MXXTRW5ITVJ?
PA-1 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP0ZW83UUN3ME20MlI2OjlizszN NXnZcFdKW0GQR1XS
EW-22 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInHTHRKSzVyPUSuN|U5PiEQvF2= MnP5V2FPT0WU
KASUMI-1 M3;SOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTD[I8yUUN3ME20MlQxOTB7IN88US=> NITPVZJUSU6JRWK=
LU-139 NUf0NphOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwN{W4Nlkh|ryP NUfYW4N2W0GQR1XS
SBC-1 NGrvW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfrSGNKSzVyPUSuPFA6ODhizszN M171[3NCVkeHUh?=
H4 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzKbWZFUUN3ME20Mlg6PDR|IN88US=> NI\lNY9USU6JRWK=
EW-11 M2HVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTVwMEiwO|Ih|ryP NHrjeG1USU6JRWK=
NBsusSR NGLRV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33CWmlEPTB;NT6xNlA2PSEQvF2= NWjz[YY5W0GQR1XS
RPMI-8226 NIraZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljqTWM2OD13LkG1NlQ1KM7:TR?= M2LNd3NCVkeHUh?=
DEL M4jlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXoTWM2OD13LkKwNFA3KM7:TR?= M{\GcnNCVkeHUh?=
ES4 NWP0UmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rMUmlEPTB;NT61NVM5QSEQvF2= MV3TRW5ITVJ?
GCT NE\lUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HofGlEPTB;NT61Olg2PiEQvF2= MUnTRW5ITVJ?
NCI-H1048 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfPcHhKSzVyPUWuPVczPzNizszN M1Ht[XNCVkeHUh?=
NCI-SNU-1 MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTZwMEKyJO69VQ>? NYPrcIY2W0GQR1XS
ES7 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfkbpVKSzVyPU[uNFM2PzdizszN NULSWYx6W0GQR1XS
SW982 M1LJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LQU2lEPTB;Nj6wPVE{PyEQvF2= NX3LXlZuW0GQR1XS
L-363 MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjuTWM2OD14LkOzPVc1KM7:TR?= M2PjRXNCVkeHUh?=
HT-1080 NHThc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZwNEm2PFMh|ryP NFXySotUSU6JRWK=
HAL-01 M{XreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTZwNUGwPUDPxE1? MlT6V2FPT0WU
NB14 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPWe49KSzVyPU[uOlQxOzlizszN NFm4OI1USU6JRWK=
EW-13 NWr5cFlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTZwN{e0NlQh|ryP M{noOnNCVkeHUh?=
NY NX61TIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nKO2lEPTB;Nj65OFYxPSEQvF2= MYPTRW5ITVJ?
NCI-SNU-5 NXezdWpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;HOpNKSzVyPUeuNVA1OzNizszN M33lRXNCVkeHUh?=
MS-1 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTdwMUe0PVQh|ryP MmnhV2FPT0WU
EW-16 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T1bmlEPTB;Nz6zNVg3OSEQvF2= M1HSTXNCVkeHUh?=
LU-65 NVTHVGpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO0UWlKSzVyPUeuOFg1OTdizszN M{fkW3NCVkeHUh?=
HGC-27 M{WyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;lZ2NCUUN3ME23MlczOTd|IN88US=> NXu0[|N6W0GQR1XS
CTB-1 NFnpTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2xTWM2OD15Lke2NVc2KM7:TR?= MXTTRW5ITVJ?
5637 NVvRV|BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M170[2lEPTB;Nz65Nlg3KM7:TR?= NGT1cmxUSU6JRWK=
U251 NWXYOm4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTdwOUSwNVYh|ryP MXXTRW5ITVJ?
HOS NXGzeYl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFizO|hKSzVyPUiuNlMxODdizszN M{m3NHNCVkeHUh?=
DOHH-2 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzwWFhOUUN3ME24MlI{PThizszN M2\ORXNCVkeHUh?=
EW-1 M2LReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRThwM{CwPFgh|ryP NX7ySZNnW0GQR1XS
BV-173 NHjINJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSyTWM2OD16LkW1OVQh|ryP NYXYcmdvW0GQR1XS
8-MG-BA M1X4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjXN3BHUUN3ME24MlY5QTh6IN88US=> NIPrZYdUSU6JRWK=
NB69 NWK2e2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRThwN{C5NlEh|ryP NVvie2toW0GQR1XS
NCI-H69 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLpTWM2OD17LkmwPVYyKM7:TR?= MYDTRW5ITVJ?
RS4-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\CS242UUN3ME2xNU4zOjB6IN88US=> NXzQe|ZbW0GQR1XS
ONS-76 M1y3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fNV2lEPTB;MUGuNlk1PyEQvF2= MWTTRW5ITVJ?
SF539 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzabY9RUUN3ME2xNU41QDh7IN88US=> Ml;nV2FPT0WU
HuO-3N1 M3LGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\STWM2OD1zMT61O|k3KM7:TR?= MlzXV2FPT0WU
NCI-H1651 NVPrOI1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF{LkOxNVUh|ryP M{P1dnNCVkeHUh?=
KARPAS-45 M{Die2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF{LkO3OkDPxE1? M1fCZXNCVkeHUh?=
SK-NEP-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\3cZRFUUN3ME2xNk41PjB7IN88US=> Ml7EV2FPT0WU
LAMA-84 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF|LkGwPVUh|ryP MXrTRW5ITVJ?
NCI-H1155 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi3TYl4UUN3ME2xN{4zQDV4IN88US=> NFvSb5JUSU6JRWK=
CTV-1 M{DSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSyTWM2OD1zMz60OFUh|ryP MknyV2FPT0WU
QIMR-WIL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrpdJZ7UUN3ME2xN{44QDF2IN88US=> M{Drc3NCVkeHUh?=
H9 NXe2ell3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLCTWM2OD1zMz64OFc2KM7:TR?= NX;OW2M5W0GQR1XS
SK-MEL-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF|LkmzOFch|ryP MnLTV2FPT0WU
HD-MY-Z MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnqdGxtUUN3ME2xOE4xPjN5IN88US=> NV:3dYVUW0GQR1XS
TI-73 M4n6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF2LkKzOVYh|ryP M4iy[XNCVkeHUh?=
JVM-3 M3\6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHIW3F7UUN3ME2xOU42PzF4IN88US=> NXLtNlRMW0GQR1XS
D-247MG NYTFWol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF3LkW5N{DPxE1? MYXTRW5ITVJ?
VA-ES-BJ MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF3Lk[wPVch|ryP NETj[GxUSU6JRWK=
NOS-1 NYjPb414T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7Y[|d{UUN3ME2xOU43PTJ{IN88US=> M{S2RnNCVkeHUh?=
MOLT-4 NV;OdIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF4Lke1NkDPxE1? M4Hyb3NCVkeHUh?=
Mo-T NYjYe5JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzqTWM2OD1zNz6wPFQ6KM7:TR?= NUPUVGtEW0GQR1XS
NCI-H1770 M37pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID2eZpKSzVyPUG3MlE2PDNizszN M3WwOnNCVkeHUh?=
COLO-320-HSR MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF5LkG4Nlch|ryP Ml\JV2FPT0WU
TE-12 NWTzb5dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF5LkewOVQh|ryP MV\TRW5ITVJ?
NCI-H82 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WyNmlEPTB;MUeuPFczQCEQvF2= NVPtVpkyW0GQR1XS
NEC8 MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF6LkGzNVYh|ryP MXfTRW5ITVJ?
HSC-3 M4rYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq1TWM2OD1zOD63OFE1KM7:TR?= NUTrNG0yW0GQR1XS
NCI-H1092 M{jmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7HflZGUUN3ME2xPE44PTl3IN88US=> MlrnV2FPT0WU
NCI-H292 M2W5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHzflFTUUN3ME2xPU4xPDh7IN88US=> NWLRd3AzW0GQR1XS
L-428 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HnXGlEPTB;MUmuOVU6KM7:TR?= MorLV2FPT0WU
LU-134-A NWTlU2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzZTWM2OD1zOT61O|Ih|ryP NXTERoduW0GQR1XS
GI-ME-N NXXZXINNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnqdm9KSzVyPUG5MlU4PDdizszN MkHEV2FPT0WU
ALL-PO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\RdVlKSzVyPUG5MlU6PzJizszN NF\GblRUSU6JRWK=
D-283MED MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfiTWM2OD1zOT65NVUh|ryP NHLoNYNUSU6JRWK=
D-423MG NF7ubFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF7Lkm5Olch|ryP M3u1fnNCVkeHUh?=
CAKI-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHhb2pKSzVyPUKwMlIzOTlizszN NX3xUVRXW0GQR1XS
ETK-1 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yxVmlEPTB;MkCuNlYyPSEQvF2= NFL2W|dUSU6JRWK=
G-402 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJyLkWzN|Qh|ryP MnyyV2FPT0WU
HL-60 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHRTWM2OD1{MT6xOlE{KM7:TR?= NY\YVJczW0GQR1XS
A2058 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjOSJpHUUN3ME2yNU41PDd5IN88US=> M1zDbnNCVkeHUh?=
CHP-212 Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJzLkmwOVEh|ryP NYLs[5ZIW0GQR1XS
KY821 M3K1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELtdZRKSzVyPUKxMlk4PSEQvF2= NEH6UmhUSU6JRWK=
TYK-nu M2\TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnCWJM2UUN3ME2yNk4xPjVzIN88US=> NVS0Vm4xW0GQR1XS
JVM-2 M3nN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jtOmlEPTB;MkKuNlk5OyEQvF2= NGnJNWhUSU6JRWK=
KU812 M2Lpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH5b4xKSzVyPUKyMlc{OTJizszN MUfTRW5ITVJ?
MKN28 NInNW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ{LkmwNVUh|ryP NUP2TZJpW0GQR1XS
ECC10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDyTWM2OD1{Mz63OFEh|ryP MX;TRW5ITVJ?
BHT-101 NFPtOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\STWM2OD1{ND6wNFA5KM7:TR?= M37KRXNCVkeHUh?=
DU-4475 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnRTWM2OD1{ND6zN|M4KM7:TR?= NFe2V5pUSU6JRWK=
769-P M2[ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITiOXhKSzVyPUK0Mlg1PjZizszN MlG1V2FPT0WU
HEC-1 NWjwcXlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\s[o9KSzVyPUK1MlQ1PSEQvF2= NUjRUVZmW0GQR1XS
MOLT-13 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13PVmlEPTB;MkWuOVM{OSEQvF2= MUjTRW5ITVJ?
8505C Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJ4LkS5O|ch|ryP NXG0[ngzW0GQR1XS
GB-1 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqyTWM2OD1{Nj63NVc3KM7:TR?= M4DYWnNCVkeHUh?=
SF126 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i5b2lEPTB;Mk[uO|Y1QCEQvF2= MnX1V2FPT0WU
A4-Fuk M2\XXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[xWGZKSzVyPUK3MlEzPzFizszN M3y4[XNCVkeHUh?=
OVCAR-8 NYXSbWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ5LkG1N|kh|ryP NHf1c4NUSU6JRWK=
NCI-H1304 NYPlVWFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ5LkW0JO69VQ>? M1j2NXNCVkeHUh?=
GR-ST NF2zSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK3c5duUUN3ME2yPE4xPDdizszN MYLTRW5ITVJ?
G-401 M{jBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LB[GlEPTB;MkiuOVA6PiEQvF2= MUPTRW5ITVJ?
LXF-289 M4PidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ6LkW2OVEh|ryP M4TmOXNCVkeHUh?=
DBTRG-05MG NV[1[WNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ6LkmyNFQh|ryP NE[yWG9USU6JRWK=
YKG-1 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuxTWM2OD1{OT64Olgh|ryP NGDDZ41USU6JRWK=
GAMG NWLEfoNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PmWmlEPTB;MkmuPVk{KM7:TR?= NID6XWhUSU6JRWK=
HCT-116 NInDNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HsdWlEPTB;M{CuNFU1QCEQvF2= M2r2TXNCVkeHUh?=
S-117 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfoTWM2OD1|MT6yNlU4KM7:TR?= NIn3c5ZUSU6JRWK=
NCI-H1693 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnzOnpJUUN3ME2zN{43PTR{IN88US=> MlvkV2FPT0WU
A427 M1e0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN|Lkm5O|Yh|ryP MWrTRW5ITVJ?
HT-29 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT5TWM2OD1|ND62NFMzKM7:TR?= M4fiT3NCVkeHUh?=
P12-ICHIKAWA MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN2Lke0PVEh|ryP NX\je5VOW0GQR1XS
CAL-51 M2PFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLvWmx{UUN3ME2zOU4xPzB7IN88US=> NU\rZpUyW0GQR1XS
Ramos-2G6-4C10 M{fnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjB[IF{UUN3ME2zOU4zPDJ3IN88US=> MVTTRW5ITVJ?
SCH NIG0Z5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTN4LkSxO|Qh|ryP M2DTUHNCVkeHUh?=
SK-MEL-24 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrLTWM2OD1|Nj65NFQ1KM7:TR?= M2[2S3NCVkeHUh?=
SW1573 NHjFUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTN6LkeyNVYh|ryP MVzTRW5ITVJ?
BALL-1 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fHWGlEPTB;M{muNlEzQSEQvF2= MljNV2FPT0WU
BE-13 NH;1TnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorsTWM2OD1|OT6zNlkh|ryP Mn;EV2FPT0WU
GI-1 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN7Lki2OFch|ryP M3fQT3NCVkeHUh?=
GOTO NF7qeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXsTWM2OD1|OT65NVM6KM7:TR?= M1PTPHNCVkeHUh?=
A673 NXrre|kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF75WVRKSzVyPUSxMlA{PDNizszN M1TLVnNCVkeHUh?=
KG-1 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TrWmlEPTB;NEOuN|k1KM7:TR?= MWXTRW5ITVJ?
GP5d NGG1bmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjDTWM2OD12ND6wOlY3KM7:TR?= NXvx[It{W0GQR1XS
MFM-223 M2\DV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfUTWM2OD12ND6xNlI5KM7:TR?= Mn;xV2FPT0WU
OAW-42 NXXjSpN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[x[mlEPTB;NESuNlY1OyEQvF2= MmK4V2FPT0WU
C8166 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn0bphMUUN3ME20OU4xQDJ{IN88US=> NGLyOWlUSU6JRWK=
LU-99A NXPY[JFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP3[4NKSzVyPUS2MlE{OjJizszN M3v5b3NCVkeHUh?=
NCI-H23 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jBe2lEPTB;NE[uNVc5PSEQvF2= NIXYe49USU6JRWK=
HO-1-N-1 M4P4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvnTWM2OD12Nz6wPVk5KM7:TR?= NGfoSpBUSU6JRWK=
A3-KAW NXX6SmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfV[pNKSzVyPUS3MlExODdizszN MYPTRW5ITVJ?
CGTH-W-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTR5LkWwOlkh|ryP M{nZfXNCVkeHUh?=
DJM-1 NVrYPFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX75OWlnUUN3ME20O{42PDF|IN88US=> MofyV2FPT0WU
A101D MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\oSWlEPTB;NEeuOlM2PyEQvF2= NX\nV5RZW0GQR1XS
BB30-HNC M1fGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr6OppKSzVyPUS4MlMxPzJizszN M4nHPHNCVkeHUh?=
T98G M3fsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn6[41iUUN3ME20PE41PjN|IN88US=> MWfTRW5ITVJ?
NCI-H1573 NH3hOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTR7LkS0OlIh|ryP NIHSbXZUSU6JRWK=
MEG-01 NUTHUGVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfGPG5KSzVyPUS5Mlc1OTFizszN M37HZ3NCVkeHUh?=
WM-115 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDmTWM2OD12OT65NlIzKM7:TR?= MX\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Olaparib有效作用于Brca1-/-;p53-/- 乳腺肿瘤 (每天按50 mg/kg剂量腹腔注射),但是对 HR缺陷的Ecad-/-;p53-/-乳腺肿瘤没有效果。Olaparib作用于携带肿瘤的鼠没有剂量限制毒性。[3] Olaparib已经用于治疗BRCA突变的肿瘤, 比如卵巢癌,胸腺癌,前列腺癌。此外,Olaparib抑制ATM缺陷的肿瘤细胞具有选择性,说明Olaparib可作为治疗ATM突变的淋巴肿瘤的潜在试剂。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

体外独立酶实验:

通过PARP-1实验测定PARP-2抑制活性,实验在96孔板上进行,PARP-2特定抗体与重组PARP-2蛋白结合。加入3H-NAD+DNA测定PARP-2活性。 冲洗后,加入闪烁剂测定3H-渗透的核糖基化。通过AlphaScreen实验测定端锚聚合酶-1, 实验中HIS标签重组TANK-1蛋白和生物素化的NAD+ 在384孔Proxi板上温育。 加入Alpha 磁珠,与HIS和生物素化的标签结合,产生邻近信号,测定信号消失的比例来计算TANK-1抑制活性。
细胞实验:

[1]

+ 展开
  • Cell lines: 胸腺癌细胞系SW620结肠, A2780卵巢,HCC1937,Hs578T,MDA-MB-231,MDA-MB-436,和T47D
  • Concentrations: 1到300 nM
  • Incubation Time: 7-14天
  • Method:

    通过成株实验测定Olaparib毒性。Olaparib溶于DMSO中,用培养基稀释。细胞接种在六孔板上,过夜使粘附。然后加入不同浓度Olaparib,温育7-14天。计算存活菌落,测定IC50值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 携带Brca1-/-;p53-/-乳腺癌的 K14cre;Brca1F/F;p53F/F
  • Formulation: 50 mg/mL储存在含10% 2-羟丙基-β-环糊精/PBS的DMSO中
  • Dosages: 50 mg/kg
  • Administration: 按10 μL/g剂量腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 434.46
化学式

C24H23FN4O3

CAS号 763113-22-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03561870 Not yet recruiting Recurrent IDH|Mutant High Grade Glioma Hospices Civils de Lyon December 1 2019 Phase 2
NCT03741426 Not yet recruiting Renal Cell Cancer CCTU- Cancer Theme|University of Cambridge|AstraZeneca|Cancer Research UK|Cambridge University Hospitals NHS Foundation Trust July 25 2019 Phase 2
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System March 1 2019 Phase 1
NCT03740893 Not yet recruiting Breast Neoplasm Institute of Cancer Research United Kingdom|AstraZeneca February 2019 Phase 2
NCT03742895 Not yet recruiting Advanced Solid Neoplasms Merck Sharp & Dohme Corp. December 17 2018 Phase 2
NCT03740165 Not yet recruiting Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms Merck Sharp & Dohme Corp.|European Network for Gynaecological Oncological Trial Groups December 14 2018 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • 回答:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • 问题 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • 回答:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • 问题 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • 回答:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)供应商 | 采购Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)价格 | Olaparib (AZD2281, Ku-0059436)生产 | 订购Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID